Kelly Lawrence W & Associates Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Merck
MRK
|
+$13M |
| 2 |
Aptiv
APTV
|
+$8.34M |
| 3 |
JPMorgan Chase
JPM
|
+$3.81M |
| 4 |
Alkermes
ALKS
|
+$2.41M |
| 5 |
Visa
V
|
+$2.03M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$10.7M |
| 2 |
SWN
Southwestern Energy Company
SWN
|
+$10.7M |
| 3 |
APA Corp
APA
|
+$10.6M |
| 4 |
AGN
Allergan plc
AGN
|
+$7.65M |
| 5 |
Vertex Pharmaceuticals
VRTX
|
+$6.27M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 23.48% |
| 2 | Technology | 17.62% |
| 3 | Healthcare | 14.5% |
| 4 | Energy | 9.7% |
| 5 | Consumer Staples | 9.69% |
Similar funds
Kelly Lawrence W & Associates's Q4 2016 Portfolio in Review
As of Q4 2016, Kelly Lawrence W & Associates held 175 positions worth $451M, down 3.4% from $467M the previous quarter. Its ten largest holdings account for 37% of the portfolio.
Kelly Lawrence W & Associates withdrew a net $29.1M in Q4 2016, closing 15 positions and reducing 46 holdings. Its most notable exit was Bristol-Myers Squibb, an estimated $10.7M position sold in full.
By sector, the portfolio is most concentrated in Financials at 23% of assets, up from 19% a quarter earlier, followed by Technology and Healthcare.
Against the trend, Kelly Lawrence W & Associates opened a new position in Aptiv worth $8.36M.
- Kelly Lawrence W & Associates's largest Q4 2016 buy was Aptiv: 124,175 shares worth $8.36M.
- Kelly Lawrence W & Associates added most to Merck in Q4 2016, an estimated $13M increase.
- Kelly Lawrence W & Associates's biggest Q4 2016 reduction was APA Corp, cutting an estimated $10.6M.
- Kelly Lawrence W & Associates fully exited Bristol-Myers Squibb in Q4 2016, selling an estimated $10.7M.
- Kelly Lawrence W & Associates's ten largest holdings make up 37% of its $451M portfolio in Q4 2016.
- Kelly Lawrence W & Associates opened 4 new positions and closed 15 in Q4 2016.
- Kelly Lawrence W & Associates's portfolio value fell 3.4% quarter-over-quarter to $451M.
Based on Kelly Lawrence W & Associates's 13F filing for Q4 2016, filed 14 Feb 2017.